Key Points
High-risk relatives of T1D have significantly more IR+ T cells than T1D or controls.
A new transgenic mouse has insulitis in the pancreas via IR on T cells, but not T1D.
Abstract
Insulin receptor (IR) expression on the T cell surface can indicate an activated state; however, the IR is also chemotactic, enabling T cells with high IR expression to physically move toward insulin. In humans with type 1 diabetes (T1D) and the NOD mouse model, a T cell–mediated autoimmune destruction of insulin-producing pancreatic β cells occurs. In previous work, when purified IR+ and IR− T cells were sorted from diabetic NOD mice and transferred into irradiated nondiabetic NOD mice, only those that received IR+ T cells developed insulitis and diabetes. In this study, peripheral blood samples from individuals with T1D (new onset to 14 y of duration), relatives at high-risk for T1D, defined by positivity for islet autoantibodies, and healthy controls were examined for frequency of IR+ T cells. High-risk individuals had significantly higher numbers of IR+ T cells as compared with those with T1D (p < 0.01) and controls (p < 0.001); however, the percentage of IR+ T cells in circulation did not differ significantly between T1D and control subjects. With the hypothesis that IR+ T cells traffic to the pancreas in T1D, we developed a (to our knowledge) novel mouse model exhibiting a FLAG-tagged mouse IR on T cells on the C57BL/6 background, which is not susceptible to developing T1D. Interestingly, these C57BL/6-CD3FLAGmIR/mfm mice showed evidence of increased IR+ T cell trafficking into the islets compared with C57BL/6 controls (p < 0.001). This transgenic animal model provides a (to our knowledge) novel platform for investigating the influence of IR expression on T cell trafficking and the development of insulitis.
Footnotes
This work was supported by National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases Grants R15-DK-103196-01 (to M.F.M.), K08 DK101755 (to K.S.), and K08 DK102526 (to B.G.) and NIH Grant P01 AI-42288-20 (to M.A.A.). Flow cytometry was performed in the Vision Research Core of the Kellogg Eye Center, supported by NIH, National Eye Institute Flow Cytometry Core Grant P30EY007003. Additional funding was provided by the Frederic and Mary Wolfe Fund for Diabetes Research-Pharmacy (to M.F.M.), the Central Ohio Diabetes Association Children’s Fund (to M.F.M.), and the Edith Briskin/Shirley K. Schlafe Foundation Taubman Emerging Scholar (to K.S.).
Portions of this article were originally presented in abstract form (74–76).
The online version of this article contains supplemental material.
- Received March 26, 2019.
- Accepted January 19, 2021.
- Copyright © 2021 by The American Association of Immunologists, Inc.
Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$37.50
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.